Lifesci Capital started coverage on shares of BlossomHill Therapeutics (NASDAQ:BLSM – Free Report) in a research note released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating and a $32.00 price objective on the stock.
Other analysts have also recently issued reports about the stock. Wall Street Zen raised shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Leerink Partners started coverage on BlossomHill Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $36.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They set an “overweight” rating and a $28.00 price objective on the stock. Guggenheim assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $30.00 price objective for the company. Finally, HC Wainwright assumed coverage on BlossomHill Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $32.20.
Get Our Latest Analysis on BLSM
BlossomHill Therapeutics Price Performance
Insiders Place Their Bets
In related news, Director Carl Gordon bought 625,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Orbimed Advisors Llc bought 625,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This trade represents a 29.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 1,573,900 shares of company stock valued at $25,181,900.
Key Stories Impacting BlossomHill Therapeutics
Here are the key news stories impacting BlossomHill Therapeutics this week:
- Positive Sentiment: Multiple bullish analyst ratings: Leerink Partners initiated coverage with an “outperform” rating and a $36 price target, while HC Wainwright began coverage with a “buy” rating and a $35 target. Guggenheim also assigned a “buy” rating and a $30 target. These targets imply substantial upside from recent trading levels. BlossomHill Therapeutics coverage and analyst ratings
- Positive Sentiment: HC Wainwright expects improving losses: The firm projects fiscal 2026 EPS of $(3.71) and fiscal 2027 EPS of $(2.99), with quarterly losses narrowing from $(0.92) in the third quarter of 2026 to $(0.69) in the third quarter and fourth quarter of 2027. HC Wainwright reiterated its “buy” rating and $35 price objective. HC Wainwright BlossomHill Therapeutics estimates
- Positive Sentiment: Upcoming investor presentations: BlossomHill announced presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events could increase visibility for its oncology pipeline and provide potential updates on development programs. BlossomHill Therapeutics conference presentations
- Neutral Sentiment: Additional research coverage: Lifesci Capital and JPMorgan Chase & Co. reportedly initiated coverage of BLSM. The new coverage may broaden institutional awareness, although ratings and price targets were not provided in the available reports. Lifesci Capital initiates coverage JPMorgan initiates coverage
About BlossomHill Therapeutics
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.
Featured Articles
- Five stocks we like better than BlossomHill Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
